BETHESDA, Md., Dec. 7, 2012 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO; NWBOW), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced the pricing of an underwritten public offering of 3,000,000 shares of common stock, and warrants to purchase up to an aggregate 1,500,000 shares of common stock, at an offering price of $4.00 per share and $0.01 per warrant. The Warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance. The shares and warrants will begin trading on The NASDAQ Capital Market today under the symbols "NWBO" and "NWBOW," respectively.
The gross proceeds to the Company from this offering are expected to be $12 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares and warrants in the offering are being sold by the Company. In addition, in connection with the offering, more than $34.5 million of the Company's debt is being converted and being removed from the Company's balance sheet as a result of such conversions.
The Company intends to use the net proceeds received from the offering to fund its research and development activities and for working capital and general corporate purposes. The Company may also use a portion of the net proceeds to repay up to $3.8 million aggregate principal amount of convertible notes and notes, comprising most of the Company's remaining outstanding debt.The offering is expected to close on December 12, 2012, subject to customary closing conditions. The Company has also granted the underwriter a 45-day option to purchase up to an additional 450,000 shares of common stock and/or 225,000 warrants to cover over-allotments, if any. In connection with its listing on The NASDAQ Capital Market, the Company's common stock will cease trading on the OTC QB.